MediWound Ltd. (MDWD) Stock Analysis & Investment Frameworks

MediWound Ltd. (MDWD) stock analysis on Invetso. Review MediWound Ltd.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.

MediWound Ltd. Company Overview

MediWound Ltd. Key Financial Metrics

About MediWound Ltd.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

MediWound Ltd. Investment Frameworks

Invetso analyzes MediWound Ltd. (MDWD) across the following frameworks:

Explore More MDWD Research